Almac Announce Potent Containment Capabilities
October 15, 2009
Addressing the continuing pharmaceutical market trend of manufacturing medication in smaller but more potent doses, Almac has successfully completed the design, manufacture and installation of state-of-the-art containment technology to facilitate the processing of potent compounds in our Product Development facility.
Our in-house engineered containment solutions employ rigid & flexible film Isolator technology around the processing zones of equipment that require containment of airborne particulates. Extensive dust monitoring exercises have determined the effectiveness of these containment solutions; and demonstrate Almac can process compounds with an OEL as low as 30 ng per m3.
We have the capability to process batch sizes ranging from 0.1Kg to 100Kg, manufacturing development, clinical & small-scale commercial solid, oral dose products.
Almac is dedicated to continually developing processes and technologies, to remain at the forefront of innovation and to offer a comprehensive outsourcing service to our clients.
– ENDS –
Almac Pharma Services
T: +44 (0) 28 3836 3363
About Almac Group:
Almac is a financially stable, privately owned organisation with over 30 years experience, it provides integrated development solutions to over 600 customers worldwide including all the world leaders in the pharmaceutical and biotechnology sectors. Their services include R&D, translational genomic services; API manufacture; formulation development; clinical trial supply and technology (IVRS/IWRS/ePRO) and commercial-scale manufacture.
The company has over 2,500 employees and is headquartered in Craigavon, Northern Ireland, where it was awarded “Business of the Year 2009”. US operations are based in Pennsylvania, North Carolina and California. Construction of the company’s new $112m North American Headquarters in PA started in July 2008 and will be completed in 2010.